Trials / Completed
CompletedNCT04379817
Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Jules Bordet Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study wil assess somatostatin receptor (SSTR) expression via the uptake of Gallium-68 labelled DOTA-conjugated SSTR targeting peptide using PET/CT imaging in multiple myeloma lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory and relapsing mutiple myeloma using the Lutetium-177 radiolabelled targeting peptide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Gallium-68 labelled DOTA-conjugated SSTR targeting peptide PET/CT | Assess somatostatin receptor expression |
Timeline
- Start date
- 2020-02-25
- Primary completion
- 2024-05-23
- Completion
- 2024-05-23
- First posted
- 2020-05-08
- Last updated
- 2024-06-27
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04379817. Inclusion in this directory is not an endorsement.